1y return+31.9%S&P 500 +20.9%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2024: $130 against $127 in the S&P 500.2
Propel Bio Management, LLCS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| PAGPPlains Gp Holdings Lp-cl | $30.9M | 16.2% | |
| ACHVAchieve Life Sciences Inc | $26.3M | 13.8% | +6.5% |
| CORTCorcept Therapeutics Inc | $11.9M | 6.2% | −7.7% |
| PHATPhathom Pharmaceuticals I | $11.4M | 6.0% | +24.9% |
| DCTHDelcath Systems Inc | $11.0M | 5.7% | −11.0% |
| MISTMilestone Pharmaceuticals | $10.0M | 5.2% | +80.4% |
| CMPSCompass Pathways PLC | $8.1M | 4.2% | −22.8% |
| KYTXKyverna Therapeutics Inc | $7.9M | 4.1% | +37.1% |
| ARTVArtiva Biotherapeutics In | $6.8M | 3.5% | +375.8% |
| ABEOAbeona Therapeutics Inc | $6.1M | 3.2% | −26.1% |
| AQSTAquestive Therapeutics In | $6.0M | 3.1% | +102.9% |
| PALIPalisade Bio Inc | $5.4M | 2.8% | +131.6% |
| IMUXImmunic Inc | $5.0M | 2.6% | New |
| IVAInventiva Sa - Adr | $4.8M | 2.5% | +76.8% |
| SABSSab Biotherapeutics Inc | $4.2M | 2.2% | +6.3% |
| OBIOOrchestra Biomed Holdings | $3.9M | 2.0% | |
| CLDXCelldex Therapeutics Inc | $3.9M | 2.0% | −21.1% |
| ZVRAZevra Therapeutics Inc | $3.6M | 1.9% | −10.2% |
| OCULOcular Therapeutix Inc | $3.5M | 1.8% | −6.4% |
| FDMT4d Molecular Therapeutics In | $3.4M | 1.8% | −33.6% |
| OVIDOvid Therapeutics Inc | $3.0M | 1.6% | +21.1% |
| EYPTEyepoint Inc | $2.7M | 1.4% | −11.2% |
| UPBUpstream Bio Inc | $2.4M | 1.3% | +2.5% |
| SCYXScynexis Inc | $2.2M | 1.2% | New |
| SLNSilence Therapeutics PLC | $2.1M | 1.1% | New |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| CMPSCompass Pathways PLC | September 30, 2025 | +146.9% | $8.1M |
| LONALeonabio Inc | September 30, 2025 | +122.0% | $1.4M |
| CORTCorcept Therapeutics Inc | March 31, 2026 | +115.7% | $11.9M |
| ZVRAZevra Therapeutics Inc | September 30, 2024 | +106.6% | $3.6M |
| MISTMilestone Pharmaceuticals | March 31, 2025 | +67.5% | $10.0M |
| ARTVArtiva Biotherapeutics In | March 31, 2026 | +50.6% | $6.8M |
| ABEOAbeona Therapeutics Inc | June 30, 2024 | +45.8% | $6.1M |
| CLDXCelldex Therapeutics Inc | September 30, 2025 | +43.8% | $3.9M |
| ACHVAchieve Life Sciences Inc | March 31, 2024 | +43.7% | $26.3M |
| FDMT4d Molecular Therapeutics In | March 31, 2026 | +42.9% | $3.4M |
Sold off last quarter
- VORVor Biopharma Inc was $5.6M
- VRDNViridian Therapeutics Inc was $4.1M
- Oculis Holding AgCUSIP H5870P102 was $3.3M
- TRVITrevi Therapeutics Inc was $2.6M
- Immunic IncCUSIP 4525EP101 was $2.6M
- CHRSCoherus Oncology Inc was $2.4M
- KLRSKalaris Therapeutics Inc was $1.7M
- Uniqure NvCUSIP N90064101 was $1.7M
- NUVBNuvation Bio Inc was $1.4M
- EVMNEvommune Inc was $1.3M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +25.0% | +14.8% |
| March 31, 2026 | −8.7% | −4.6% |
| December 31, 2025 | +5.5% | +2.4% |
| September 30, 2025 | +9.6% | +7.8% |
| June 30, 2025 | +3.1% | +10.5% |
| March 31, 2025 | −4.2% | −4.6% |
| September 30, 2024 | +22.1% | +5.4% |
| June 30, 2024 | −10.2% | +4.0% |
| March 31, 2024 | +33.0% | +10.0% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Propel Bio Management, LLC Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1969764&type=13F-HR&dateb=&owner=include&count=40CIK 1969764
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1969764/000182912626008753/Filed August 13, 2026 · accession 0001829126-26-008753